174 results about "Acute kidney injury" patented technology

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.

The invention relates to the use of human fat-derived mesenchymal stem cells in the treatment of diseases in kidney and ocular fundus. The invention provides the use of the human fat-derived mesenchymal stem cells in cell preparation for treating diseases in kidney and/or ocular fundus, such as acute kidney injury, renal fibrosis, renal tubular epithelial cell damage, retinosis, diabetic retinopathy and retinal tear. The cell preparation can promote the repair of kidney structure and damaged eyeball pathologic structure with good effect.

Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.

A catheter devices/systems and methods therefrom are described herein for treating acute kidney injury, especially the contrast-induced acute kidney injury wherein the devices prevent the contrast dyes from entering into kidney and/or facilitate blood flow of kidney by said catheter system.

In one embodiment, the present invention is directed to methods for diagnosis of acute kidney injury (AKI) and hepatorenal syndrome (HRS) in cirrhosis patients, and to methods for distinguishing between AKI and/or HRS and/or other kidney diseases in cirrhosis subjects. In another embodiment, the present invention is directed to prognostic methods for predicting disease-specific mortality in cirrhosis patients. In some aspects, the diagnostic and prognostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range.

The invention discloses application of andrographolidume to preparing medicine for treating acute liver injury. The andrographolidume can remarkably inhibit liver injury induced by semen canavaliae A, the liver cell apoptosis induced by the ssemen canavaliae A and inflammatory response of liver, and can also be used for treating the liver injury induced by the semen canavaliae A. The invention firstly provides the evidence of the andrographolidume for treating the liver injury induced by the semen canavaliae A in an animal model, definitudes that the liver cell apoptosis caused by the semen canavaliae A is inhibited by inhibiting excessive active oxygen species caused by the semen canavaliae A, and prompts that the andrographolidume has the protection function on the acute liver injury in clinical.

The invention belongs to the medical field and particularly relates to an acute kidney injury diagnosis technology, a B cell epitope peptide of human NGAL (Neutrophil Gelatinase Associated Lipocalin) and a hybridoma cell prepared by same, and an application of the B cell epitope peptide and a specific antibody thereof and an immune complex of the specific antibody in preparing diagnostic reagent for acute kidney injury. The B cell epitope peptide prepared by the invention immunizes a monoclonal antibody prepared by adopting a rat and has the advantages of high purity (The SDS (Sodium Dodecyl Sulfate)-PAGE (PolyAcrylamide Gel Electrophoresi) detection purity is more than 96 percent), high valence (the ELISA (Enzyme-Linked Immuno Sorbent Assay) valence reaches 1:256000), good specificity, mass preparation and the like; and through the monoclonal antibody and a polyclonal antibody prepared by the B cell epitope peptide, the B cell epitope peptide can be used for detecting the content of the NGAL in the urine of a patient, for example, by adopting a double antibody sandwich ELISA reaction mode, a double antibody sandwich structure formed by an enzyme labeled human anti-NGAL monoclonal antibody, an enzyme labeled plate package anti-NGAL polyclonal antibody and a measured sample NGAL antigen is detected.

The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject.

The invention discloses a hybridoma cell strain generating an anti-human NGAL specific monoclonal antibody and a monoclonal antibody generated by the same. The hybridoma cell strain is generated in a way that after an amino acid sequence shown by SEQIDNO:1 immunizes a Balb/c rat, a spleen B lymph cell and a myeloma cell of the rat are fused for further cultivation. The antibody can be used for the immunity detection of the NGAL. Based on the invention, an immunity detection reagent for the NGAL can be developed and used for diagnosing and detecting acute kidney injury and other diseases.

It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G₀/G₁ cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G₀/G₁ cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells

The invention provides a colloidal gold immunocolorimetry kit for detecting retinol conjugated protein (RBP) and a preparation method of the kit and belongs to the field of in-vitro diagnostic reagents. The kit is used for judging whether the situation of individual acute kidney injury occurs or not. According to the method, colloidal gold particles are adopted as a carrier, a retinol conjugated protein (RBP for short) antibody and the colloidal gold particles are coupled, RBP protein in a sample makes contact with the coupled gold particles in a corresponding detection device, an antigen-antibody-gold compound is formed, the light absorbance of the gold particles under detection wavelength is changed, the change amount of the light absorbance is positively correlated with the concentration of RBP protein, and then the purpose of detecting RBP protein in the sample is achieved. The kit has high analysis sensitivity.

The invention discloses application of phospholipid rich in DHA (Docosahexaenoic Acid) to a product for improving the acute kidney injury. According to the invention, DHA phospholipid is prepared by using sleeve-fish roes as raw materials, separation and conversion are further carried out, and purity of the prepared phospholipid is all 90% or above. A preparation method of sleeve-fish phosphatidylcholine extract is low in cost and simple in step, uses a small volume of organic solvent, and generates little organic solvent pollution to the environment. Animal experiments prove that when a mousesuffering from the acute kidney injury is only supplemented and intervened with 200 to 400mg/kg DHA-rich phosphatidylcholine, life time of the mouse suffering from the acute kidney injury is obviously prolonged and the kidney tissue injury degree of the mouse is reduced, which proves that the phospholipid rich in DHA can be applied to the product for improving the acute kidney injury.

The present invention relates to the field of nephrology. More specifically, the present invention provides compositions and methods useful for the study and treatment of acute kidney injury. In one embodiment, the present invention provides a knockout animal whose genome comprises a deletion of exon 2 and exon 3 of kelch-like ECH-associated protein 1 (KEAP1) in T-cells. In another embodiment, a method for treating a subject diagnosed with AKI comprising the steps of (a) isolating T-cells from the subject; (b) activating Nrf2 expression in the isolated T-cells; and (c) administering the T-cells back to the subject.

The invention discloses an application of a cat isaria mycelium in the preparation for a medicine treating acute kidney injury caused by cis-platinum. An experimental result displays that after mice are injected with cis-platinum and patients are chemo-treated by cis-platinum, the CRE and BUN levels in the serums thereof are obviously increased, meaning that the cis-platinum can cause an acute kidney injury to the mice and the chemo-treated patients; after the mice injected with cis-platinum are perfused with cat isaria mycelium dry powder and the patients chemo-treated by cis-platinum take cat isaria mycelium dry powder, the CRE and BUN levels in the serums thereof are obviously decreased, meaning that the cat isaria mycelium has a remarkable treatment function to the acute kidney injury caused by cis-platinum. The invention provides the application of the cat isaria mycelium in the preparation for a medicine treating acute kidney injury caused by cis-platinum, and the cat isaria mycelium can be further developed to be an assistant medicine in the cis-platinum chemotherapy.

The invention provides a construction method of a contrast agent induced acute kidney injury animal model. A clinically commonly used low permeability contrast agent is used in the construction method to make the stable CI-AKI model within a short time, so interferences of other confounding factors are effectively avoided, bases are provided for further researches of the pathologic and physiologic mechanisms, the molecular cytology and the molecular biology of the CI-AKI, and bases are provided for early prevention and treatment of CI-AKI of clinic patients.